Pretreatment with IFN-&#945; increases resistance to imatinib mesylate in patients with chronic myelocytic leukemia.

Xiao, Yin; Hu, Hui-hua; Wang, Hong-xiang; Zhu, Xiao-jian; Zou, Ping; Chen, Zhi-chao; Zhong, Zhao-dong; Li, Wei-ming; You, Yong

Pretreatment with IFN-α increases resistance to imatinib mesylate in patients with chronic myelocytic leukemia.

Xiao, Yin; Hu, Hui-hua; Wang, Hong-xiang; Zhu, Xiao-jian; Zou, Ping; Chen, Zhi-chao; Zhong, Zhao-dong; Li, Wei-ming; You, Yong.

Acta Pharmacol Sin ; 33(7): 979-80, 2012 Jul.

Article in En | MEDLINE | ID: mdl-22684027

Subject(s)

Antineoplastic Agents/pharmacology; Drug Resistance, Neoplasm/drug effects; Immunologic Factors/pharmacology; Interferon-alpha/pharmacology; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy; Piperazines/pharmacology; Protein Kinase Inhibitors/pharmacology; Pyrimidines/pharmacology; Antineoplastic Agents/therapeutic use; Benzamides; Humans; Imatinib Mesylate; Immunologic Factors/therapeutic use; Interferon-alpha/therapeutic use; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics; Piperazines/therapeutic use; Point Mutation/drug effects; Protein Kinase Inhibitors/therapeutic use; Pyrimidines/therapeutic use; Retrospective Studies

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Piperazines / Pyrimidines / Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Interferon-alpha / Drug Resistance, Neoplasm / Protein Kinase Inhibitors / Immunologic Factors / Antineoplastic Agents Type of study: Observational_studies Limits: Humans Language: En Journal: Acta Pharmacol Sin Journal subject: FARMACOLOGIA Year: 2012 Type: Article

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google